Type 2 Diabetes. Type 2 diabetes mellitus
Conditions
Sponsors
Sanandaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Iranian nationality Age 18 years and above Diagnosed with type 2 diabetes for at least 6 months Glycated hemoglobin level of 8% or higher
Exclusion criteria
Exclusion criteria: Complications of type 2 diabetes that disrupt the patient's care process, such as blindness, dialysis, severe stroke Medical history of cognitive disorders like dementia or Alzheimer's Uncontrolled hypertension above 180/110 millimeter of mercury Hearing and visual impairments Hemolytic anemia Hemoglobinopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asprosin. Timepoint: Evaluation of Mean Asprosin Levels (nanogram per milliliter) Before the Intervention and 3 Months After the Completion of the Intervention. Method of measurement: Blood test using ELISA kit.;Insulin resistance. Timepoint: Assessment of insulin resistance before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using ELISA kit (HOMA-IR index). | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean serum BUN levels (milligrams per deciliter). Timepoint: Mean serum BUN levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic kit with urease-glutamate dehydrogenase (GLDH) method.;Body mass index. Timepoint: Mean Body mass index levels (kilogram per square meter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Measurements will be performed by trained staff using calibrated digital scales and stadiometers.;Mean changes in systolic blood pressure (millimeter of mercury). Timepoint: Mean systolic blood pressure levels (millimeters of mercury) before the intervention and 3 months after the intervention. Method of measurement: Calibrated digital sphygmomanometer.;Mean changes in diastolic blood pressure (millimeters of mercury). Timepoint: Mean diastolic blood pressure levels (millimeters of mercury) before the intervention and 3 months after the intervention. Method of measurement: Calibrated digital sphygmomanometer.;Mean serum triglyceride levels (milligrams per deciliter). Timepoint: Mean Serum triglyceride levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum total cholesterol levels (milligrams per deciliter). Timepoint: Mean serum total cholesterol levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum LDL-C levels (milligrams per deciliter). Timepoint: Mean serum LDL-C levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using direct enzymatic assay kits.;Mean serum HDL-C levels (milligrams per deciliter). Timepoint: Mean | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Golnaz Azami
Sanandaj University of Medical Sciences
Outcome results
None listed